{
  "ticker": "AT1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977872",
  "id": "02977872",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250807",
  "time": "0934",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmjg0kzwgkhb.pdf",
  "summary": "- **Order secured**: US$410,000 (A$630,000) for Pascal cassettes from Lumos Diagnostics.  \n- **Strategic agreement**: Lumos has a 6-year US distribution deal with PHASE Scientific for Pascal-enabled FebriDx\u00ae test, targeting up to **US$316m in sales** (contingent on CLIA waiver and minimum order quantities).  \n- **Regulatory progress**: FebriDx\u00ae has FDA 510k clearance; CLIA waiver study expected completion in August 2025.  \n- **Exclusive supply**: Atomo is the sole manufacturer/licensor of Pascal cassettes for FebriDx\u00ae.  \n\n*Material impact*: Potential revenue upside from US market expansion tied to Lumos contract.  \n\n*Omitted*: Management commentary, operational background (non-material to valuation/capital structure).",
  "usage": {
    "prompt_tokens": 916,
    "completion_tokens": 177,
    "total_tokens": 1093,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-06T23:46:45.009771"
}